To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Arthaffect, Breakthrough Product Targeting Degenerative Joint Conditions URL: http://www.pslgroup.com/dg/D36A.htm Doctor's Guide October 28, 1996
CHESTERFIELD, Mo, Oct. 28, 1996 -- Reliv International (NASDAQ: RELV), a marketer of high-quality nutritional supplements, introduces Arthaffect(TM), a revolutionary product for the nation's 40 million people with serious joint problems and 50 million athletes subject to joint problems. The product contains Arthred(TM), which has been proven effective as a treatment in Germany for thousands of sufferers (a) with a variety of joint problems. More than $10 million in clinical trials have proven the effectiveness of Arthred, Arthaffect's patented ingredient, in fighting degenerative joint conditions. Arthaffect is available in the United States exclusively through Reliv International. "There remains no known cure for arthritis," Dr. Carl W. Hastings, Reliv Executive Vice President, stressed. "Traditional products on the market simply treat the symptoms, such as pain, and often provide side effects. In stark contrast, Arthaffect is a functional food that focuses on the source of the problems. It is the ideal method for caring for joints and fighting problems associated with degenerative joint conditions, all with no known side effects." For several years, Arthred has been widely used by thousands of arthritis sufferers and athletes in Germany, where the protein-based substance has been the subject of double-blind, parallel group clinical trials by some of Europe's leading researchers. Involving hundreds of participants suffering from joint pain, stiffness, weakness, sensitivity to cold weather, exercise pain, fatigue, night pain, swelling, etc., the studies demonstrated significant improvement in each area among those whose daily regimen included 7 to 10 grams of Arthred. Improvement generally is noticed in one to three months. The U.S. Food and Drug Administration has approved a protocol for a major study in this country to look at the effects of Arthred on joint problems. Arthaffect, available as a tasteless, odorless powder which can be mixed with any beverage, is described by Dr. Hastings as "a protein derived from the enzymatic hydrolyzation of collagen. It consists of a series of 19 amino acids joined in chains by peptide bonds. These same amino acids comprise the framework of human cartilage, and are required for its generation." Because Arthaffect has been clinically reported to nutritionally support healthy joint function, it is recommended not only for those with severe joint conditions, but also for athletes, joggers, walkers and others who experience constant wear and tear on their joints. Arthaffect also has been shown to have a direct positive effect on the endurance and long-term condition of joints. "Arthaffect is a functional food," said Hastings, "a new area that explodes with promise as medical professionals, scientists, and the largest food companies in the world recognize the ability of certain foods to affect not just our overall health, but specific functions of our bodies. With the support of well-balanced, scientifically accepted clinical studies showing positive and consistent results, functional foods will become the solution for many traditionally challenging health problems." Reliv International is a network marketing firm that sells high-quality nutritional supplements, weight-management products, and other nutritional and skin care products directly to consumers. More than 50,000 independent distributors market Reliv products throughout the United States, Canada, Mexico, Australia, New Zealand and the United Kingdom. All products feature an unconditional money-back guarantee. For further information, call 888/735-4855. (a) National Health Interview Survey, Arthritis Foundation --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.